Introduction
Recently, there has been increasing demand for ligand-receptor interactions in the area of medical screening. In this field, screening is mostly carried out by solid-phase methods; however, there is generally some insufficiency in such screenings as bound/free separation becomes a rate-determining process. In addition, with screening in the solid phase, bioactive molecules are often inactivated because of immobilization through the active sites, and the denaturing of entire or parts of molecules caused by the immobilization processes, as has also been shown in our laboratory. This problem can hardly be avoided even in the protein chip system expected as a very rapid screening method in the field. It is significant to compare data for the interaction by a liquid-phase method with those by a solid-phase method quantitatively, considering denaturing the active sites and steric hindrance by a solid phase. Therefore, the development of a medical screening method in solution or liquid phase would have great importance.
Here, we focus on fluorescence polarization analysis (FPA) as a candidate of a medical screening method. [1] [2] [3] [4] FPA is a powerful tool for the analysis of protein-protein interactions in a homogeneous system. It also has a great advantage that the sample volume required for the analysis can be reduced. In FPA, a fluorescently labeled molecule is excited by polarized light, and the emitted fluorescence is depolarized due to the rotational Brownian motion of the labeled molecule. The degree of depolarization is firmly affected by the effective volume of the molecule. With FPA, the bound/free separation process, which is necessary with solid-phase methods, can be omitted. Therefore, FPA is considered to be essentially suited to high-throughput medical screening. 5 Until now, although there have been some reports of FPA for ligand-receptor interactions, few have been reported concerning FPA for a membrane binding receptor. 6 This is probably because the protein tends to be unstable when it is chemically extracted from membranes of living cells, or is genetically reproduced from the extracellular domain of the membrane binding receptor. Here, we think that the extracellular domain of the receptor can be stabilized by way of fusing with the Fc region of immunoglobulin G (IgG), so that the fusion protein will remain active in the liquid-phase for FPA. In this paper we adopt bone marrow stromal cell antigen 1 (BST-1, CD157) as a model receptor for medical screening. BST-1 is known as a glycosylphosphatidylinositol (GPI) anchored membrane receptor identified by expression cloning using monoclonal antibodies against bone marrow stromal cell lines derived from rheumatoid arthritis patients. 7 Phage display screening has already been carried out, and two peptides obtained; 8 Fluorescence polarization analysis (FPA) of a liquid-phase method was carried out with a glycosylphosphatidylinositol (GPI) anchored membrane receptor bone marrow stromal cell antigen 1 (BST-1, CD157) as a model receptor for medical screening. A soluble receptor, BST1-Fc, was prepared by fusing the extracellular domain of BST-1 and the Fc region of human immunoglobulin G (IgG). The binding curves of BST1-Fc with a fluorescently labeled ligand peptide, or its three derivatives, were developed using ordinary FPA in the liquid phase. The obtained dissociation constants (Kd) were comparable with those reported as measured with SPR of a solid-phase method, except for one derivative peptide with Kd larger than 7000 nM. Competitive FPA was carried out, and it was demonstrated that a very weak interaction, which would be difficult to detect with SPR or other solid-phase methods, could be analyzed with both ordinary and competitive FPA. 14 derivatives of SNP-1 have been prepared by alanine scanning and their dissociation constants with BST-1 have been analyzed by surface plasmon resonance (SPR) assay. 9 In this research, we prepared a soluble receptor, BST1-Fc, by fusing the extracellular domain of BST-1 and the Fc region of human IgG. We carried out ordinary FPA for the binding between BST1-Fc and fluorescently labeled SNP-1, or some typical derivatives. Subsequently, competitive FPA was carried out. Here, we discuss the activity and the usefulness of the fusion protein for FPA. Thus, the affinity between BST1-Fc and the derivatives of SNP-1 is compared quantitatively for the first time, based on past data by a solid-phase method and the original data by the liquid-phase method.
Materials and Methods

Preparation of peptides and DNA
The prototype peptide (SNP-1) and three derivative peptides (H01A, G06A, R10A) chemically synthesized were purchased from Sigma-Genosys; all of those were labeled with fluorescein at the amino terminal. These peptides were represented as FL-SNP1, FL-H01A, FL-G06A and FL-R10A, respectively. Nonlabeled SNP-1 and R10A (NL-SNP1 and NL-R10A) were also prepared. The amino acid sequences are given in Table 1 . Here, the underlined A in H01A, G06A and R10A indicates the replaced amino acid of alanine. The arbitrary sequence of synthesized single-stranded oligo-DNA (ssDNA) labeled with fluorescein at 5′ end was purchased from Sigma-Genosys for a negative control reagent ( Table 1) .
Preparation of BST1-Fc
A DNA fragment including the coding region (amino acid residues 1 -297) of human BST-1 cDNA was prepared using PCR with the BST-1 bacurovirus transfer vector 8 as a template. The primers 5′-CTC GAG ATG GCG GCC CAG GGG TGC GCG-3′ were used for the upstream primer and 5′-GAA TTC GTA TAA AGA CTT GGG GCT TTT-3′ for the downstream primer. The PCR product was ligated with the pCR2.1-TOPO vector (TOPO TA cloning Kit, Invitrogen), followed by digestion using XhoI and EcoRI. The XhoI-EcoRI fragment including the human BST-1 cDNA was subcloned into the same sites of the IgG-Fc fusion protein expression vector (designate as pTeuIgGBST-1a2). 10 The plasmid DNA, pTeuIgGBST-1a2 was introduced into COS-1 cells by transient transfection using 
FPA measurement
All FPA activities were carried out using a microplate reader (ULTRA Evolution, Tecan). The central wavelengths for excitation and emission were 485 nm and 535 nm, respectively.
For ordinary FPA, BST1-Fc solutions were serially diluted using PBS. Each of the diluted samples was mixed with a fluorescently labeled peptide solution in wells of the microplate (384 Well Plate, Low Volume, Black, Corning). For competitive FPA, the inhibitor peptides were preferably diluted using PBS. BST1-Fc and fluorescently labeled H01A (FL-H01A) were then mixed, followed by the addition of an inhibitor peptide solution. The inhibitor peptides used were non-labeled SNP-1 (NL-SNP1) and R10A (NL-R10A). Measurements were all carried out using 10 μl of the total solution at 25˚C after 20 min of incubation. Here, ordinary FPA means FPA using a fluorescein-labeled peptide and the receptor; competitive FPA means FPA using a fluorescein labeled peptide, the receptor and non-labeled peptide as a competitor.
Results and Discussion
Dissociation constants of BST1-Fc/SNP-1 derivatives with ordinary FPA
BST1-Fc solutions were serially diluted and mixed with 10 nM of fluorescently labeled peptides (Table 1) , and subjected to ordinary FPA. A 21 mer of fluorescently labeled ssDNA (FL-DNA) was used as a negative control for the peptides. In the case that the concentration of BST1-Fc was as high as 200 nM, the background signal due to scattering or self-fluorescence was not ignorable. Therefore, the intensities of parallel and perpendicular polarized light were compensated using each value obtained by measurements for the same concentrations of the BST1-Fc solution without the peptides. After compensation for the background signal, the fluorescence polarization (FP) values were calculated (plotted in Fig. 1 ). The dissociation constants (Kd) of the interaction between these labeled peptides (or ssDNA) and BST1-Fc were calculated by fitting to the Klotz equation (listed in Table 2 ), and were compared with those obtained by SPR analysis. 9 As can be seen in Fig. 1 , the FP values increased with increasing BST1-Fc concentration for all the fluorescently labeled peptides or ssDNA used. Apparent sigmoidal curves by fitting are shown for the labeled prototype SNP-1 (FL-SNP1) and G06A (FL-G06A). Labeled H01A seems to show an inflection point near the highest BST1-Fc concentration,
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ANALYTICAL SCIENCES SEPTEMBER 2006, VOL. 22 Table 1 Ligand peptides and control SNP-1 (Prototype)  H2N-HSQISGKYQRYLKDA-COOH  H01A  H2N-ASQISGKYQRYLKDA-COOH  G06A  H2N-HSQISAKYQRYLKDA-COOH  R10A H2N-HSQISGKYQAYLKDA-COOH DNA 5′-GGT GAT GCT ACA TAC GGA AAG-3′ Name Sequence although the FP values are lower than those for FL-SNP1 or FL-G06A. It is surely suggested that there would be a weak interaction between FL-H01A and BST1-Fc. For these three peptides (SNP-1, G06A and H01A), Kd obtained by FPA show good agreement with those obtained by SPR in the order given in Table 2 . Although Kd obtained by the two methods are inverted for prototype SNP-1 and G06A, we consider that this is due to the difference in the solid and liquidphase conditions, to the influence of the fluorescent labeling of peptides, or to fusing the receptor with the Fc region.
In any case, a derivative peptide, G06A, which has one amino acid replaced for the prototype SNP-1, showed a strong interaction as the prototype (Tables 1 and 2 ). On the other hand, the labeled R10A (FL-R10A) showed a weak increase in the FP value with increasing the BST1-Fc concentration, for which Kd could be assessed as ca. 8000, while it could not be by SPR. In this experiment, the negative control of ssDNA (FL-DNA) also showed a very weak interaction, the Kd of which was ca. 14000 nM ( Table 2) . We consider that the extremely weak specific or non-specific interaction could be evaluated by FPA, and that these results could be obtained mainly because FPA is a liquid-phase method and uses no immobilized sorbent or substrate. Additionally, the difference of proteins used-one is a fusion protein of BST-1 and Fc region of human antibody and the other is soluble form of BST-1-can slightly cause the binding manner of ligand peptide and receptor. 9 
Competitive FPA
Competitive FPA was carried out by adding non-labeled prototype SNP-1 (NL-SNP1) or R10A (NL-R10A) as inhibitors, following premixing 3 μM of BST1-Fc and 10 nM of FL-H01A. Competitive FPA was carried out for serially diluted inhibitors. The FP values obtained are plotted in Fig. 2 for the case after compensation of the background signal as well as ordinary FPA described above.
With increasing inhibitor concentrations, the FP values decreased and showed sigmoidal curves for both NL-SNP1 and NL-R10A. These results indicate that FL-H01A, which is prebound to BST1-Fc, is dissociated with an increase of the inhibitors. It is interesting that not only NL-SNP1, but also NL-R10A, induce the dissociation of FL-H01A, even though NL-R10A has not shown any detectable signal increase by SPR measurements. 9 From this result, we consider that competitive FPA using a soluble receptor can detect extremely weak interacting ligands that are difficult to confirm by solid-phase screening methods, such as SPR or ELISA.
To quantitatively compare the binding of the two inhibitors to BST1-Fc, Kd were assessed (listed in Table 2 ). In this table, the Kd value of NL-R10A is comparable to that obtained with ordinary FPA. However, the Kd value of NL-SNP1 was 2.4 times larger than that obtained with ordinary FPA, and the FP value decreased more steeply than that of NL-R10A in accordance with the increase of the inhibitor concentration (Fig.  2) . We consider the reason to be that the replacement of NL-SNP1 for fluorescent H01A is corporative because SNP-1 binds the soluble form of BST-1 at 2:2 stoichiometry. To prove this supposition, further detailed experiments are needed.
Conclusion
The soluble receptor BST1-Fc of the fusion protein was prepared using genetic engineering, and binding curves of the receptor with the fluorescently labeled prototype peptide (SNP-1) or three derivative peptides (H01A, G06A and R10A) were obtained in solution using ordinary FPA of a liquid-phase method. The dissociation constants for the prototype and two derivatives were comparable to those already reported, as measured with SPR, but that for one derivative peptide (R10A) was determined to be more than 7000 by FPA, which could not be determined by SPR or other solid-phase methods. Moreover, competitive FPA was carried out using the prototype peptide (SNP-1) or a derivative peptide (R10A) as an inhibitor against the premixed conjugate of the receptor and a labeled derivative H01A. We found that a very weak interaction, such as between BST1-Fc and R10A, which would be difficult to detect with SPR or other solid-phase methods, can be analyzed with both ordinary and competitive FPA. Because neither the immobilization process nor bound/free separation is necessary, FPA is thus essentially suited for the high-throughput screening of ligand-receptor interactions. Besides, considering an evaluation of the weak interaction, the method of this research may be applied for screening candidate drug chemicals, which could control the levels of the effect.
